KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Inventory (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Inventory for 6 consecutive years, with $5.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Inventory fell 33.25% year-over-year to $5.4 million, compared with a TTM value of $5.4 million through Dec 2025, down 33.25%, and an annual FY2025 reading of $5.4 million, down 33.25% over the prior year.
  • Inventory was $5.4 million for Q4 2025 at Biocryst Pharmaceuticals, up from $5.2 million in the prior quarter.
  • Across five years, Inventory topped out at $29.8 million in Q1 2024 and bottomed at $4.4 million in Q2 2024.
  • Average Inventory over 3 years is $15.4 million, with a median of $7.8 million recorded in 2024.
  • The sharpest move saw Inventory crashed 83.54% in 2024, then grew 13.35% in 2025.
  • Year by year, Inventory stood at $28.7 million in 2023, then plummeted by 71.81% to $8.1 million in 2024, then plummeted by 33.25% to $5.4 million in 2025.
  • Business Quant data shows Inventory for BCRX at $5.4 million in Q4 2025, $5.2 million in Q3 2025, and $5.0 million in Q2 2025.